Listeria monocytogenes non-coding RNA

NurExone Launches Licensing Efforts for ExoTherapy Platform

Retrieved on: 
Wednesday, February 14, 2024

TORONTO and HAIFA, Israel, Feb. 14, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “Company” or “NurExone”), a biopharmaceutical company, announced today the commencement of efforts to license its proprietary ExoTherapy platform for creating nanodrugs by loading therapeutic molecular cargo into exosomes.

Key Points: 
  • TORONTO and HAIFA, Israel, Feb. 14, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “Company” or “NurExone”), a biopharmaceutical company, announced today the commencement of efforts to license its proprietary ExoTherapy platform for creating nanodrugs by loading therapeutic molecular cargo into exosomes.
  • The Company’s ExoTherapy platform for exosome-based therapy production includes: (i) large-scale exosome production using the Company’s dedicated bioreactor, (ii) synthesis of therapeutic cargo and (iii) processes to load the therapeutic cargo, creating nanodrugs.
  • Dr. Lior Shaltiel, CEO of NurExone, commented, “Exosomes have the potential to be the ultimate drug delivery system.
  • ExoPTEN, for patients with acute spinal cord injuries, is being developed on our platform, and we expect great success through licensing our technology for other indications!”.

NextRNA Therapeutics Strengthens Board of Directors with Appointment of Lori Friedman, PhD

Retrieved on: 
Tuesday, September 26, 2023

NextRNA Therapeutics, a biotechnology company unlocking the potential of long non-coding RNAs (lncRNAs) to develop transformative medicines for multiple diseases with an initial focus on oncology and neurology, today announced the appointment of Lori Friedman, PhD, to its Board of Directors.

Key Points: 
  • NextRNA Therapeutics, a biotechnology company unlocking the potential of long non-coding RNAs (lncRNAs) to develop transformative medicines for multiple diseases with an initial focus on oncology and neurology, today announced the appointment of Lori Friedman, PhD, to its Board of Directors.
  • “We are thrilled to welcome Dr. Lori Friedman to NextRNA’s Board of Directors.
  • lncRNAs represent a vast and promising class of targets to address cancer and neurological diseases, among numerous other diseases.
  • Dr. Friedman earned a PhD in molecular and cell biology from UC Berkeley and completed a post-doctoral fellowship at Cambridge University in England.

Latest Updates of 7 Viva's Portfolio Companies

Retrieved on: 
Friday, July 28, 2023

WATERTOWN, Mass.-- Riparian Pharmaceuticals, a Viva Biotech portfolio company, is a biotechnology company focused on discovering novel therapeutics for cardiovascular diseases. Riparian today announced it has entered into an exclusive license agreement and research agreement with Pfizer.

Key Points: 
  • WATERTOWN, Mass.-- Riparian Pharmaceuticals, a Viva Biotech portfolio company, is a biotechnology company focused on discovering novel therapeutics for cardiovascular diseases.
  • Riparian today announced it has entered into an exclusive license agreement and research agreement with Pfizer.
  • In exchange for exclusive rights to a Riparian preclinical program, Pfizer will make upfront and milestone payments, as well as pay royalties on sales of resulting therapeutics.
  • DTx Pharma utilizes its groundbreaking FALCON™ platform, a conjugated oligonucleotide technology using fatty acid ligands, to tackle the delivery challenges of oligonucleotide therapies.

ORIEN Member Presentations at 2023 ASCO Demonstrate Unique Value of Aster Insights' Data

Retrieved on: 
Tuesday, May 30, 2023

TAMPA, Fla., May 30, 2023 /PRNewswire/ -- Aster Insights ("the Company"), the leading provider of technology-enabled data and analytics solutions for oncology discovery, today announced its participation as a research partner at the American Society of Clinical Oncology (ASCO) Annual Meeting, June 2-6, 2023 in Chicago, IL. An oral presentation and three posters will be presented at this year's ASCO meeting, utilizing the lifetime patient-consented longitudinal clinicogenomic data from the Company's Oncology Research Information Exchange Network® (ORIEN) AVATAR program. These presentations highlight the research partnerships and collaboration of Aster Insights and 18 premier cancer centers that comprise ORIEN.

Key Points: 
  • An oral presentation and three posters will be presented at this year's ASCO meeting, utilizing the lifetime patient-consented longitudinal clinicogenomic data from the Company's Oncology Research Information Exchange Network® ( ORIEN ) AVATAR program.
  • These presentations highlight the research partnerships and collaboration of Aster Insights and 18 premier cancer centers that comprise ORIEN.
  • "We are thrilled to be selected for these diverse presentations at ASCO that showcase the incredible work of ORIEN and Aster Insights," said Jill Kolesar, PharmD, Director of the Precision Medicine Center at the Markey Cancer Center and Chair of the ORIEN Executive Advisory Committee.
  • For more information about our ASCO presentations, please contact Aster Insights at: [email protected]

HAYA Therapeutics Adds World-Leading Cardiologist and Dark Genome Pioneer to Advisory Boards

Retrieved on: 
Thursday, February 16, 2023

HAYA Therapeutics, SA , a company developing RNA-guided programmable precision medicines focused on long non-coding RNAs (lncRNAs), today announced that Ahmad Masri, M.D., M.S.

Key Points: 
  • HAYA Therapeutics, SA , a company developing RNA-guided programmable precision medicines focused on long non-coding RNAs (lncRNAs), today announced that Ahmad Masri, M.D., M.S.
  • View the full release here: https://www.businesswire.com/news/home/20230216005353/en/
    Dr. Ahmad Masri, a Cardiologist and Physician Scientist at the Oregon Health & Science University’s Knight Cardiovascular Institute, has been named the newest member of HAYA Therapeutic’s Clinical Advisory Board.
  • (Photo: Business Wire)
    “The expansion of our advisors with Ahmad and Cedric, and the creation of our Clinical Advisory Board marks a significant milestone for HAYA,” said Samir Ounzain, Ph.D., Co-founder and CEO of HAYA Therapeutics.
  • “HAYA has pioneered a novel approach of targeting disease drivers within the dark genome, and I’m looking forward to working with their team in identifying and understanding relevant clinically-translatable dark genome targets.”

RNA-Targeted Novel Drug Modalities Market Research Report 2022: RNA Editing, Epitranscriptomics, Direct RNA Targeting, Splicing Modulation, Translation Regulation, lncRNA & regRNA Targeting - ResearchAndMarkets.com

Retrieved on: 
Thursday, January 5, 2023

The "RNA-Targeted Novel Drug Modalities Based on RNA Editing, Epitranscriptomics, Direct RNA Targeting, Splicing Modulation, Translation Regulation, lncRNA & regRNA Targeting & More: a Landscape Analysis of Technologies, Targets, Business and Financing from An Industry Perspective" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "RNA-Targeted Novel Drug Modalities Based on RNA Editing, Epitranscriptomics, Direct RNA Targeting, Splicing Modulation, Translation Regulation, lncRNA & regRNA Targeting & More: a Landscape Analysis of Technologies, Targets, Business and Financing from An Industry Perspective" report has been added to ResearchAndMarkets.com's offering.
  • This report provides you with a landscape description and analysis of discovery and development of novel drug modalities targeting RNA from an industry perspective.
  • The report evaluates the partnering deals of pharmaceutical companies with RNA-targeted drug discovery companies regarding scope of the agreement and economic terms which allows to identify preferences of major pharmaceutical companies for RNA-targeted novel drug modalities.
  • In this context, recent attention has turned to looking for regulators of RNA function, including small molecules and biologics.

Clarivate Identifies Seven Innovators in New RNA Technology Companies to Watch Report

Retrieved on: 
Tuesday, October 25, 2022

LONDON, Oct. 25, 2022 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, today announced the release of a new report, RNA Technology Companies to Watch. The report identifies seven emerging innovators in the field of medical science who are solving for undruggable disease targets. The report draws on data and analytics from BioWorld, an award-winning suite of news services delivering actionable intelligence on the most innovative therapeutics and medical technologies in development, published by Clarivate. Leveraging Clarivate and BioWorld data and insights paired with analysis of drug benefits, financing, R&D activity and more, this report explores what sets these companies apart and why they are companies to watch.

Key Points: 
  • The report identifies seven emerging innovators in the field of medical science who are solving for undruggable disease targets.
  • Leveraging Clarivate and BioWorld data and insights paired with analysis of drug benefits, financing, R&D activity and more, this report explores what sets these companies apart and why they are companies to watch.
  • To learn more about the RNA Technology Companies to Watch report, visit here .
  • The RNA Technology Companies to Watch is based on Clarivate's current expectations reflective of existing data, but actual results derived from companies featured in the Report and herein may differ.

Clarivate Identifies Seven Innovators in New RNA Technology Companies to Watch Report

Retrieved on: 
Tuesday, October 25, 2022

LONDON, Oct. 25, 2022 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, today announced the release of a new report, RNA Technology Companies to Watch. The report identifies seven emerging innovators in the field of medical science who are solving for undruggable disease targets. The report draws on data and analytics from BioWorld, an award-winning suite of news services delivering actionable intelligence on the most innovative therapeutics and medical technologies in development, published by Clarivate. Leveraging Clarivate and BioWorld data and insights paired with analysis of drug benefits, financing, R&D activity and more, this report explores what sets these companies apart and why they are companies to watch.

Key Points: 
  • The report identifies seven emerging innovators in the field of medical science who are solving for undruggable disease targets.
  • Leveraging Clarivate and BioWorld data and insights paired with analysis of drug benefits, financing, R&D activity and more, this report explores what sets these companies apart and why they are companies to watch.
  • To learn more about the RNA Technology Companies to Watch report, visit here .
  • The RNA Technology Companies to Watch is based on Clarivate's current expectations reflective of existing data, but actual results derived from companies featured in the Report and herein may differ.

Portfolio Highlights: Clinical and Financial Updates of ABM, F5, AceLink, HAYA, Regenacy, and Arthrosi

Retrieved on: 
Wednesday, September 28, 2022

ABM-1310, ABM Therapeutic's proprietary clinical candidate developed as a next-generation BRAF inhibitor, is a highly selective, highly water-soluble, orally administrated, and brain-penetrant small molecule BRAF inhibitor.

Key Points: 
  • ABM-1310, ABM Therapeutic's proprietary clinical candidate developed as a next-generation BRAF inhibitor, is a highly selective, highly water-soluble, orally administrated, and brain-penetrant small molecule BRAF inhibitor.
  • F5 Therapeutics, which invested and incubated by Viva BioInnovator, was recently awarded the first Servier FAST Discovery Award.
  • Winning this award means F5 stood out from 23 applications, indicating the industry's recognition of F5's innovative treatment methods in the field of biomedicine.
  • AceLink Therapeutics, Inc. (AceLink), invested and incubated by Viva BioInnovator, is an innovative biopharmaceutical company developing transformative therapies for genetic diseases.

HAYA Therapeutics Appoints Brian C. Thomas, Ph.D., as Chairperson of the Board of Directors

Retrieved on: 
Thursday, September 15, 2022

HAYA Therapeutics, SA , a company developing RNA-guided programmable precision medicines focused on long non-coding RNAs (lncRNAs), today announced that Brian C. Thomas, Ph.D., has joined HAYA as Chairperson of the Board of Directors.

Key Points: 
  • HAYA Therapeutics, SA , a company developing RNA-guided programmable precision medicines focused on long non-coding RNAs (lncRNAs), today announced that Brian C. Thomas, Ph.D., has joined HAYA as Chairperson of the Board of Directors.
  • View the full release here: https://www.businesswire.com/news/home/20220914006014/en/
    HAYA Therapeutics, SA, a company developing RNA-guided programmable precision medicines focused on long non-coding RNAs (lncRNAs), today announced that Brian C. Thomas, Ph.D., has joined HAYA as Chairperson of the Board of Directors.
  • (Photo: Business Wire)
    As an innovator in the field of gene editing, Brian has built a world-renowned company in Metagenomi.
  • HAYA Therapeutics is a precision medicines company developing RNA-guided programmable therapeutics targeting the regulatory genome for serious health conditions including cardiovascular disease and cancer.